Schnichels Lab

Neuroprotection & Drug Delivery

Home » Labs » Clinical Research Labs » Schnichels Lab » Members » Sven Schnichels

Sven Schnichels

SurnameSchnichels
First nameSven
NationalityGerman
Present position and titleGroup Leader "Neuroprotection & Drug Delivery"
Dr. rer. nat.

Business address

Institute for Ophthalmic Research
University of Tübingen
Elfriede-Aulhorn-Strasse 7
D-72076 Tübingen,
Germany

Phone: +49 (0)7071 29-87888
E-mail: sven.schnichels[at]med.uni-tuebingen.de

Academic Education

Year Degree University Field of study
2006 - 2010 Dr. rer. nat. (PhD) Eberhard Karls University, Tübingen, Germany Ophthalmology / Neuroscience
2000 - 2005 Diploma University of Hohenheim, Stuttgart, Germany Biology

Professional Experience

Year

Degree University Field of study

Since 2016

Group Leader

University Eye Hospital Tübingen

Ophthalmology / drug-delivery

Since 2013

Laboratory Head

University Eye Hospital Tübingen

Ophthalmology / drug-delivery

2011 - 2013

Laboratory Head Preclinical Research

University Eye Hospital Tübingen

Ophthalmology / drug-delivery

2009 - 2011

Post-Doc

University Eye Hospital Tübingen

Ophthalmology / Neuroscience

2006 - 2009

PhD position

University Eye Hospital Tübingen

Ophthalmology / Neuroscience

Professional Activities and Functions

Academic Awards

since 2019 European Leadership Development Programme (EuLDP), European Society of Ophthalmology (SOE)
2021

DOG-Glaucoma Research Award sponsored by Santen, Germany

2021

Dr. Gaide-AMD-Award, German Retina Society

2019 Research Award of the Boni-Tschönhens-Foundation
2019 Poster award: Makula Update 2019, Novartis, Germany
2018 DOG-Patent-Award of the Deutsche Ophthalmologische Gesellschaft sponsored by Heidelberg Engineering
2018 AECOS European Research Award 2018: American-European Congress of Ophthalmic Surgery
2016 Poster award: Research Colloquium of the Medical Faculty Tübingen 2016
2015 Poster award: 113. Congress of the Deutsche Ophthalmologische Gesellschaft
2015 Science4Life (Business Plan Competition), Winner Idea + Concept Phase
2015 2. Scientific Prize Verein Rheinisch-Westfälischer Augenärzte
2014 Poster award: 112. Congress of the Deutsche Ophthalmologische Gesellschaft
2014 2. Place: Science2Start from BioRegio STERN Management
2013 1. Place: EYEnovative Research Prize from Novartis
2012 1. Place: NGI (Netherlands Genomics Initiative) Venture Challenge
2011 Poster award: 109. Congress of the Deutsche Ophthalmologische Gesellschaft
2010 Poster award: Tübingen Outer Retina Conference (TORC)
2010 Poster award: Young Researcher Vision Camp 2010

Memberships

Since 2018 International Society for Eye Research
Since 2012 Deutsche Ophthalmologische Gesellschaft (DOG)
Since 2010 Association for Research in Vision and Ophthalmology (ARVO)
Since 2010 Neurowissenschaftliche Gesellschaft (NWG)
Since 2007 Society for Neuroscience (SfN)

Travel Grants

2011 – 2019 7x DAAD: ARVO Meetings in Baltimore, Denver, Orlando, Seattle, Fort Lauderdale, USA & Vancouver, Canada
2012 GlaxoSmithKline Foundation to the FENS Meeting 2012 in Barcelona, Spain
2009 Reinhold-und-Maria-Teufel-Stiftung to the Neuroscience Meeting 2009 in Chicago, USA

Committees

Since 2021

Project group German Center for Health Research: Ophthalmology (DOG)

Since 2019 Scientific Committee European Vison Camp
Since 2019 Programme Committee, German Ophthalmic Society (DOG)

Since 2019

Junior Academy Medical Faculty, Tübingen, Germany

Since 2018 Scientific Advisor: Robert Bosch GmbH, Germany
Since 2018 Board of Directors, German Ophthalmic Society (DOG)
Since 2018 Speaker YoungDOG (German Ophthalmic Society)

Additional information

Ad-Hoc Reviewer (Selection)

Investigative Ophthalmology & Visual Science; Scientific Reports; Acta Ophthalmologica; Experimental Eye Research; Clinical and Experimental Ophthalmology; Organic & Biomolecular Chemistry; Journal of Neuroinflammation; Journal of Molecular Neuroscience; Nanotoxicology; Journal of Visualized Experiments; Vision Research; International Journal of Molecular Sciences; Journal of Pharmaceutical and Biomedical Analysis, Drug Design, Development and Therapy; Regulatory Toxicology and Pharmacology; Cell and Tissue Research; Cellular Physiology and Biochemistry; Pharmaceutics; Cells; BMC Ophthalmology; Journal of Ocular Pharmacology and Therapeutics; Der Ophthalmologe; Colloids and Surfaces B: Biointerfaces; International Journal of Nanomedicine; Biomedical Optics Express;

Foundations and Funding organisations:

Ernst und Berta Grimmke Stiftung; Deutsche Ophthalmologische Gesellschaft; fwo; Ghent University; Christian Doppler Forschungsgesellschaft, Österreichische Forschungsförderungsgesellschaft; Health Research Charities Ireland (HRCI)-Health Research Board (HRB),

Patents

A. Herrmann; J.W. de Vries; M.S. Spitzer; S.O. Schnichels, Means and Methods for Ocular Drug Delivery, PCT/NL2014/050634, EP3057572B1 and US10285939B2

Past and Current Funding

2021 - 2022

Research grant: GO-Bio Initial, BMBF, Germany: REVeyeVE

2019 - 2023 Research grant from Novartis Pharma GmbH, Germany
2020 - 2021

Research grant: Helmut Ecker Stiftung, Germany

2019 - 2020 Intramural research grant of the ƒortüne-Program of the Tübingen medical faculty
2019 Industry grant from DORC & University Leiden, The Netherlands
2018 - 2020  Industry grant from Robert-Bosch GmbH, Germany
2017 - 2019 Research grant from the PRO RETINA-Stiftung, Germany
2016 - 2019 Research grant from the SET-Stiftung, Germany
2016 - 2019 Research grant: Ministry of Rural Affairs & Consumer Protection Baden-Württemberg, Germany
2014 - 2017 Research grant (EXIST-Forschungstransfer): German federal ministry for economic affairs & energy
2014 - 2016 Research grant from the SET-Stiftung, Germany
2013 - 2016 Research grant from the Bundesinstitut für Risikobewertung (BfR), Germany
2013 - 2014 Intramural research grant of the ƒortüne-Program of the Tübingen medical faculty
2013 - 2016 Coaching grant from the European Social Fund (ESF)
2012 - 2014 Industry grant from Clanotech, Sweden
2011 - 2016 Industry grants (3) from CROMA, Austria

Selected Publications

  1. Schnichels S+, Hurst J, de Vries JW, Ullah S, Frößl K, Gruszka A, Löscher M, Bartz-Schmidt KU, Spitzer MS, Herrmann A. Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles. ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9445-9456. Epub 2021 Feb 2. IF: 9,229
  2. Schnichels S+, Paquet-Durand F, Löscher M, Tsai T, Hurst J, Joachim SC, Klettner A.  Retina in a dish: Cell cultures, retinal explants and animal models for common diseases of the retina. Prog Retin Eye Res. 2020 Jul 25:100880. Online ahead of print. IF: 21,198; Review
  3. Schnichels S+, Hurst J, de Vries JW, Ullah S, Gruszka A, Kwak M, Löscher M, Dammeier S, Bartz-Schmidt KU, Spitzer MS, Herrmann A. Self-assembled DNA nanoparticles loaded with travoprost for glaucoma-treatment. Nanomedicine. 2020 Oct;29:102260. Epub 2020 Jul 3. IF: 6,458
  4. Hurst J, Mueller-Buehl AM, Hofmann L, Kuehn S, Herms F, Schnichels S +#, Joachim SC. iNOS-inhibitor Driven Neuroprotection in a Porcine Retina Organ Culture Model J Cell Mol Med. 2020 Apr;24(7):4312-4323. Epub 2020 Mar 4. IF: 5,310
  5. Wu Z, Troll J, Jeong HH, Wei Q, Stang M, Ziemssen F, Wang Z, Dong M, Schnichels S, Qiu T & Fischer P A swarm of slippery micropropellers penetrates the vitreous body of the eye. Sci Adv. 2018 Nov 2;4(11):eaat4388. IF: 12,804
  6. de Vries JW, Schnichels S*, Hurst J, Strudel L, Gruszka A, Kwak M, Bartz-Schmidt KU, Spitzer MS & Herrmann A DNA nanoparticles for ophthalmic drug delivery. Biomaterials. 2018 Mar;157:98-106. Epub 2017 Nov 29. IF: 10,279
  7. Schnichels S+, Dorfi T, Schultheiss M, Arango-Gonzalez B, Bartz-Schmidt KU, Januschowski K, Spitzer MS & Ziemssen F Ex-vivo-examination of ultrastructural changes in organotypic retina culture using near-infrared imaging and optical coherence tomography. Exp Eye Res. 2016 Jun;147:31-6. Epub 2016 Apr 21. IF: 3,332
  8. Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS & Aisenbrey S Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells. Br J Ophthalmol. 2013 Jul;97(7):917-23. Epub 2013 May 17. IF: 2,809
  9. Gaub P, Joshi Y, Wuttke A, Naumann U, Schnichels S, Heiduschka P & Di Giovanni S The histone acetyltransferase p300 promotes intrinsic axonal regeneration. Brain. 2011 Jul;134(Pt 7):2134-48. IF: 9,457
  10. Heiduschka P, Schnichels S, Fuhrmann N, Hofmeister S, Schraermeyer U, Wissinger B & Alavi MV Retinal ganglion cells are primarily affected in an animal model of OPA1 associated autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1424-31 2009 Oct 15. IF: 3,466